Key Takeaways
- • Collate raised $95 million in Series A funding led by Redpoint Ventures, achieving a valuation approaching $1 billion just 17 months after exiting stealth mode, bringing total funding to $125 million.
- • The company has secured approximately 50 enterprise customers across pharma, medtech, and biotech sectors since its first enterprise deal in May 2025, demonstrating rapid market adoption for AI-driven documentation automation.
- • Collate's platform addresses a critical operational bottleneck in life sciences by automating regulatory paperwork, clinical trial documentation, and product development filings—a compliance-heavy workflow segment experiencing accelerating demand for AI efficiency.
- • Founded by Surbhi Sarna, a two-time entrepreneur and former Y Combinator partner, the company builds GxP-compliant, AI-native software designed to execute documentation tasks with minimal manual intervention in highly regulated environments.
- • Lead investor Redpoint Ventures is joined by returning investors First Round Capital and Conviction Partners, signaling strong institutional confidence in the life sciences automation market opportunity.
Summary
Collate, a San Francisco-based artificial intelligence company, has closed a $95 million Series A funding round led by Redpoint Ventures, achieving a valuation approaching $1 billion. The funding brings the company's total capitalization to $125 million since its founding and represents a significant validation of its business model just 17 months after emerging from stealth mode. The round was co-led by returning investors First Round Capital and Conviction Partners, indicating sustained confidence from early-stage backers in the company's execution and market opportunity.
The company addresses a structural inefficiency in life sciences operations: the time-consuming and heavily regulated documentation workflows required across clinical trials, regulatory filings, and product development. Collate has developed AI-powered software designed to automate these documentation and compliance tasks while maintaining GxP (Good Practice) standards mandated by regulatory bodies. This automation capability is positioned to significantly reduce administrative burden and accelerate timelines in drug development and medical device commercialization—processes where documentation delays directly impact time-to-market and operational costs.
Market adoption has accelerated rapidly following the company's first enterprise customer engagement in May 2025. Collate now serves approximately 50 enterprise customers spanning major pharmaceutical companies, medical device manufacturers, and biotech firms. This customer concentration in regulated, high-stakes segments suggests strong product-market fit within sophisticated institutional buyers operating under strict compliance requirements. The speed of customer acquisition and the caliber of enterprise adoption indicate a meaningful market pull for AI-driven solutions in life sciences documentation.
The company was founded by Surbhi Sarna, an experienced entrepreneur who previously served as a partner at Y Combinator and has founded multiple ventures. Her background in both startup building and venture capital provides credibility with institutional customers and investors in assessing the complexity of life sciences operations. The founding team's demonstrated ability to navigate regulated industries and secure marquee customer relationships has been instrumental in achieving near-unicorn valuation status in less than two years of public operation.
The company addresses a structural inefficiency in life sciences operations: the time-consuming and heavily regulated documentation workflows required across clinical trials, regulatory filings, and product development. Collate has developed AI-powered software designed to automate these documentation and compliance tasks while maintaining GxP (Good Practice) standards mandated by regulatory bodies. This automation capability is positioned to significantly reduce administrative burden and accelerate timelines in drug development and medical device commercialization—processes where documentation delays directly impact time-to-market and operational costs.
Market adoption has accelerated rapidly following the company's first enterprise customer engagement in May 2025. Collate now serves approximately 50 enterprise customers spanning major pharmaceutical companies, medical device manufacturers, and biotech firms. This customer concentration in regulated, high-stakes segments suggests strong product-market fit within sophisticated institutional buyers operating under strict compliance requirements. The speed of customer acquisition and the caliber of enterprise adoption indicate a meaningful market pull for AI-driven solutions in life sciences documentation.
The company was founded by Surbhi Sarna, an experienced entrepreneur who previously served as a partner at Y Combinator and has founded multiple ventures. Her background in both startup building and venture capital provides credibility with institutional customers and investors in assessing the complexity of life sciences operations. The founding team's demonstrated ability to navigate regulated industries and secure marquee customer relationships has been instrumental in achieving near-unicorn valuation status in less than two years of public operation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.